ARVN ARVINAS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1655759 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-11.8%
TTM net income YoY83.8%
TTM EPS YoY90.1%
Revenue 3-yr CAGR18.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-12.1%
Net margin-3.5%
FCF margin-58.0%
EBITDA margin-11.2%
Returns
ROE-1.8%
ROA-1.3%
ROIC (approx.)-5.9%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets15.4%
Debt / equity0.00x
Current ratio8.39x
Interest coverage—
Cash quality & payout
Operating cash flow / net income16.66x
Accruals ratio20.5%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $500,000 | $249.70M | $15.60M | $9.50M | $41.90M | $22.40M | $188.80M | $59.20M |
| R&D expense | $46.90M | $52.60M | $60.30M | $61.10M | $64.70M | $68.60M | $90.80M | $83.30M |
| SG&A expense | $12.60M | $24.00M | $19.10M | $23.00M | $21.00M | $25.30M | $26.60M | $34.10M |
| Operating income | -$59.10M | $164.10M | -$63.80M | -$74.60M | -$43.80M | -$71.50M | $71.40M | -$58.20M |
| Interest expense | $0 | $0 | — | — | $0 | $0 | $0 | $0 |
| Pretax income | -$53.70M | $169.60M | -$57.50M | -$67.20M | -$34.80M | -$61.50M | $83.10M | -$45.50M |
| Income tax | $200,000 | $200,000 | $100,000 | $200,000 | $300,000 | -$300,000 | $200,000 | -$400,000 |
| Net income | -$53.90M | $169.40M | -$57.60M | -$67.40M | -$35.10M | -$61.20M | $82.90M | -$45.10M |
| EBITDA | -$58.50M | $164.80M | -$63.10M | -$73.90M | -$43.00M | -$70.70M | $72.10M | -$57.10M |
| EPS (basic) | -0.82 | 2.61 | -0.90 | — | -0.48 | -0.84 | 1.14 | — |
| EPS (diluted) | -0.82 | 2.58 | -0.90 | — | -0.48 | -0.84 | 1.14 | — |
| Weighted avg. shares (diluted) | 65.40M | 65.70M | 64.00M | — | 73.20M | 73.00M | 72.70M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $88.00M | $94.30M | $87.30M | $142.90M | $101.50M | $114.90M | $81.00M | $100.50M |
| Short-term investments | $470.40M | $473.60M | $527.60M | $542.50M | $686.10M | $746.30M | $873.30M | $938.90M |
| Receivables | $1.80M | $50.30M | $1.80M | $1.00M | $20.30M | $500,000 | $400,000 | $5.70M |
| Current assets | $587.60M | $652.20M | $630.70M | $700.70M | $826.30M | $889.50M | $979.70M | $1.07B |
| PP&E, net | $4.60M | $5.00M | $5.50M | $5.20M | $5.40M | $6.10M | $6.70M | $7.00M |
| Total assets | $607.50M | $675.10M | $647.50M | $717.90M | $844.30M | $909.30M | $1.00B | $1.09B |
| Current liabilities | $70.00M | $82.50M | $115.90M | $142.50M | $144.90M | $157.80M | $214.00M | $229.80M |
| Short-term debt | $200,000 | $200,000 | $200,000 | $200,000 | $200,000 | $200,000 | $200,000 | $200,000 |
| Long-term debt | $200,000 | $300,000 | $300,000 | $400,000 | $400,000 | $500,000 | $500,000 | $600,000 |
| Total debt | $400,000 | $500,000 | $500,000 | $600,000 | $600,000 | $700,000 | $700,000 | $800,000 |
| Total liabilities | $93.70M | $112.90M | $260.70M | $284.00M | $279.90M | $300.00M | $341.00M | $529.70M |
| Shareholders' equity | $513.80M | $562.20M | $386.80M | $433.90M | $564.40M | $609.30M | $660.10M | $561.70M |
| Net debt | -$87.60M | -$93.80M | -$86.80M | -$142.30M | -$100.90M | -$114.20M | -$80.30M | -$99.70M |
| Shares outstanding | 65.50M | 65.30M | 64.50M | 63.50M | 70.80M | 73.20M | 73.00M | 68.80M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10.40M | -$48.30M | -$69.20M | -$30.40M | -$59.10M | -$95.40M | -$88.90M | -$84.10M |
| Capital expenditure | -$200,000 | $200,000 | $1.30M | $200,000 | $100,000 | $1.20M | $400,000 | $300,000 |
| Free cash flow | -$10.20M | -$48.50M | -$70.50M | -$30.60M | -$59.20M | -$96.60M | -$89.30M | -$84.40M |
| Investing cash flow | $4.20M | $54.90M | $13.70M | $145.80M | $63.50M | $128.80M | $69.50M | $98.90M |
| Financing cash flow | $400,000 | $400,000 | -$100,000 | -$74.00M | -$17.80M | $500,000 | -$100,000 | $500,000 |
| Depreciation & amortization | $600,000 | $700,000 | $700,000 | $700,000 | $800,000 | $800,000 | $700,000 | $1.10M |
| Stock-based compensation | $5.90M | $5.90M | $12.10M | $8.50M | $10.10M | $10.40M | $15.00M | $23.30M |
| Share buybacks | — | — | — | $74.10M | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.